PROGRAM CHAIR
Dean Wingerchuk, MD
Professor and Chair, Department of Neurology
Mayo Clinic
Phoenix/Scottsdale, AZ
PROGRAM OVERVIEW
This enduring innovative educational activity will be specifically designed to meet the unique educational needs of US-based neurologists, ophthalmologists, neuro-ophthalmologists, optometrists, pharmacists, emergency medicine clinicians, nurses, nurse practitioners, and physician’s assistants who diagnose and manage patients with neuromyelitis optica spectrum disorders (NMOSD). Through this thoughtfully designed and pedagogically effective programming, we aim to help healthcare providers: assess the burden of NMOSD on patients regarding HRQoL and disability, review the role of AQP4 in NMOSD and its implications for treatment selection, identify and review the potential biomarkers in the CNS of patients with NMOSD, and evaluate evidence from clinical trials assessing available and emerging therapies for the treatment of patients with NMOSD.
TARGET AUDIENCE
This activity is intended to meet the educational needs of US-based neurologists, ophthalmologists, neuro-ophthalmologists, optometrists, pharmacists, emergency medicine clinicians, nurses, nurse practitioners, and physician assistants who diagnose and manage patients with NMOSD.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Assess the burden of NMOSD on patients regarding HRQoL and disability
- Review the role of AQP4 in NMOSD and its implications for treatment selection
- Identify and review the potential biomarkers in the CNS of patients with NMOSD
- Evaluate evidence from clinical trials assessing available and emerging therapies for the treatment of patients with NMOSD
ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
JOINT ACCREDITATION STATEMENT
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Med Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
NURSES (ANCC) CREDIT DESIGNATION
Amedco LLC designates this activity for a maximum of 1.0 ANCC contact hour.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIP(S)
Faculty Member | Disclosures |
Dean Wingerchuk, MD | Discloses that he has received consulting fees from Novartis, Syneos Health, UCB Pharma, Reistone Biopharma, Alexion, Bristol Myers Squibb, Imcyse, Merck, Roche, Horizon, and Genentech. |
All relevant financial relationships have been mitigated.
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.
Staff Planners and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME/CE activity:
- Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
- Lisa Kuhns, PhD, Medical Director for Med Learning Group, has nothing to disclose.
- Nicole Longo, DO, FACOI, VP of Med/Sci Services & Learner Engagement for Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
- Marissa Mays-Verman, Program Manager for Med Learning Group, has nothing to disclose.
- Alexis Klinger, Program Coordinator for Med Learning Group, has nothing to disclose.
- Aimee Meissner, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity.
In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation.
Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at [email protected]
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at https://www.medlearninggroup.com/privacy-policy/=
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
RELEASED DATE: August 31, 2023
EXPIRATION DATE: August 31, 2024
Copyright © 2023 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
PROGRAM CHAIR
Dean Wingerchuk, MD
Professor and Chair, Department of Neurology
Mayo Clinic
Phoenix/Scottsdale, AZ
CONTRIBUTER
Sumaira Ahemd
NMOSD Patient
Founder & Executive Director of The Sumaira Foundation
Somerville, MA
PROGRAM OVERVIEW
This enduring innovative educational activity will be specifically designed to meet the unique educational needs of US-based neurologists, ophthalmologists, neuro-ophthalmologists, optometrists, pharmacists, emergency medicine clinicians, nurses, nurse practitioners, and physician’s assistants who diagnose and manage patients with neuromyelitis optica spectrum disorders (NMOSD). Through this thoughtfully designed and pedagogically effective programming, we aim to help healthcare providers: assess the burden of NMOSD on patients regarding HRQoL and disability, review the role of AQP4 in NMOSD and its implications for treatment selection, identify and review the potential biomarkers in the CNS of patients with NMOSD, and evaluate evidence from clinical trials assessing available and emerging therapies for the treatment of patients with NMOSD.
TARGET AUDIENCE
This activity is intended to meet the educational needs of US-based neurologists, ophthalmologists, neuro-ophthalmologists, optometrists, pharmacists, emergency medicine clinicians, nurses, nurse practitioners, and physician assistants who diagnose and manage patients with NMOSD.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Assess the burden of NMOSD on patients regarding HRQoL and disability
ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the virtually live activity.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education ACCME Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIP(S)
Faculty Member | Disclosures |
Dean Wingerchuk, MD | Discloses that he has received consulting fees from Novartis, Syneos Health, UCB Pharma, Reistone Biopharma, Alexion, Bristol Myers Squibb, Imcyse, Merck, Roche, Horizon, and Genentech. |
Sumaira Ahemd | Has nothing to disclose. |
All relevant financial relationships have been mitigated.
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.
Staff Planners and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME/CE activity:
- Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
- Lisa Kuhns, PhD, Medical Director for Med Learning Group, has nothing to disclose.
- Nicole Longo, DO, FACOI, VP of Med/Sci Services & Learner Engagement for Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
- Marissa Mays-Verman, Program Manager for Med Learning Group, has nothing to disclose.
- Alexis Klinger, Program Coordinator for Med Learning Group, has nothing to disclose.
- Aimee Meissner, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity.
In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation.
Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at [email protected]
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at https://www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
Please listen to the podcast below:
RELEASED DATE: August 31, 2023
EXPIRATION DATE: August 31, 2024
Copyright © 2023 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
PROGRAM CHAIR
Dean Wingerchuk, MD
Professor and Chair, Department of Neurology
Mayo Clinic
Phoenix/Scottsdale, AZ
PROGRAM OVERVIEW
This enduring innovative educational activity will be specifically designed to meet the unique educational needs of US-based neurologists, ophthalmologists, neuro-ophthalmologists, optometrists, pharmacists, emergency medicine clinicians, nurses, nurse practitioners, and physician’s assistants who diagnose and manage patients with neuromyelitis optica spectrum disorders (NMOSD). Through this thoughtfully designed and pedagogically effective programming, we aim to help healthcare providers: assess the burden of NMOSD on patients regarding HRQoL and disability, review the role of AQP4 in NMOSD and its implications for treatment selection, identify and review the potential biomarkers in the CNS of patients with NMOSD, and evaluate evidence from clinical trials assessing available and emerging therapies for the treatment of patients with NMOSD.
TARGET AUDIENCE
This activity is intended to meet the educational needs of US-based neurologists, ophthalmologists, neuro-ophthalmologists, optometrists, pharmacists, emergency medicine clinicians, nurses, nurse practitioners, and physician assistants who diagnose and manage patients with NMOSD.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Review the role of AQP4 in NMOSD and its implications for treatment selection
- Identify and review the potential biomarkers in the CNS of patients with NMOSD
ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the virtually live activity.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education ACCME Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIP(S)
Faculty Member | Disclosures |
Dean Wingerchuk, MD | Discloses that he has received consulting fees from Novartis, Syneos Health, UCB Pharma, Reistone Biopharma, Alexion, Bristol Myers Squibb, Imcyse, Merck, Roche, Horizon, and Genentech. |
All relevant financial relationships have been mitigated.
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.
Staff Planners and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME/CE activity:
- Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
- Lisa Kuhns, PhD, Medical Director for Med Learning Group, has nothing to disclose.
- Nicole Longo, DO, FACOI, VP of Med/Sci Services & Learner Engagement for Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
- Marissa Mays-Verman, Program Manager for Med Learning Group, has nothing to disclose.
- Alexis Klinger, Program Coordinator for Med Learning Group, has nothing to disclose.
- Aimee Meissner, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity.
In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation.
Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at [email protected]
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at https://www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
Please listen to the podcast below:
RELEASED DATE: August 31, 2023
EXPIRATION DATE: August 31, 2024
Copyright © 2023 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
PROGRAM CHAIR
Dean Wingerchuk, MD
Professor and Chair, Department of Neurology
Mayo Clinic
Phoenix/Scottsdale, AZ
CONTRIBUTER
Brian Weinshenker, MD
Professor of Neurology, Department of Neurology
University of Virginia
Charlottesville, VA
PROGRAM OVERVIEW
This enduring innovative educational activity will be specifically designed to meet the unique educational needs of US-based neurologists, ophthalmologists, neuro-ophthalmologists, optometrists, pharmacists, emergency medicine clinicians, nurses, nurse practitioners, and physician’s assistants who diagnose and manage patients with neuromyelitis optica spectrum disorders (NMOSD). Through this thoughtfully designed and pedagogically effective programming, we aim to help healthcare providers: assess the burden of NMOSD on patients regarding HRQoL and disability, review the role of AQP4 in NMOSD and its implications for treatment selection, identify and review the potential biomarkers in the CNS of patients with NMOSD, and evaluate evidence from clinical trials assessing available and emerging therapies for the treatment of patients with NMOSD.
TARGET AUDIENCE
This activity is intended to meet the educational needs of US-based neurologists, ophthalmologists, neuro-ophthalmologists, optometrists, pharmacists, emergency medicine clinicians, nurses, nurse practitioners, and physician assistants who diagnose and manage patients with NMOSD.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Evaluate evidence from clinical trials assessing available and emerging therapies for the treatment of patients with NMOSD
ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the virtually live activity.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education ACCME Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIP(S)
Faculty Member | Disclosures |
Dean Wingerchuk, MD | Discloses that he has received consulting fees from Novartis, Syneos Health, UCB Pharma, Reistone Biopharma, Alexion, Bristol Myers Squibb, Imcyse, Merck, Roche, Horizon, and Genentech. |
Brian Weinshenker, MD | Discloses that he has received royalties from RSR Ltd. Consulting fees from CANbridge, Pharmaceuticals, Horizon, Genentech/Roche, and Mitsubishi Tanabe. He also has Intellectual Property / is a Patent Holder for neuromyelitis optica-IgG for diagnosis of neuromyelitis optica spectrum disorders. He was on a speaker’s bureau for Horizon, and Roche. He also served on the adjudication committee for Alexion and UCB Biosciences. |
All relevant financial relationships have been mitigated.
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.
Staff Planners and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME/CE activity:
- Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
- Lisa Kuhns, PhD, Medical Director for Med Learning Group, has nothing to disclose.
- Nicole Longo, DO, FACOI, VP of Med/Sci Services & Learner Engagement for Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
- Marissa Mays-Verman, Program Manager for Med Learning Group, has nothing to disclose.
- Alexis Klinger, Program Coordinator for Med Learning Group, has nothing to disclose.
- Aimee Meissner, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity.
In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation.
Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at [email protected]
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at https://www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
Please listen to the podcast below:
RELEASED DATE: August 31, 2023
EXPIRATION DATE: August 31, 2024
Copyright © 2023 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.